Home › Therapeutic areas › Oncology › Colorectal Cancer

Colorectal Cancer (27 companies)

Companies with an active program in Colorectal Cancer.

Ticker Company Therapeutic areas Programs Lead stage Mkt cap Programs
ADAG Adagene Oncology 1 Phase 2 $99.4M 10
AKTS Aktis Oncology Oncology 1 Phase 1 $910M 10
AVBP ArriVent BioPharma Oncology 1 Phase 3 $553M 7
BCAX Bicara Therapeutics Oncology 1 Phase 2 $637M 4
BBOT BridgeBio Oncology Therapeutics Oncology 2 Phase 1 $156M 6
CMPX Compass Therapeutics Oncology 1 Phase 2 $109M 15
CBIO Crescent Biopharma Oncology 1 Phase 2 $507M 10
CYDY CytoDyn NeurologyOncology 1 Phase 2 $367M 3
CTMX CytomX Therapeutics Oncology 1 Phase 1 $423M 7
ELTX Elicio Therapeutics Oncology 1 Phase 2 $40.5M 6
EXEL Exelixis CardiovascularOncology 1 Approved $16.7B 23
IBRX ImmunityBio Infectious DiseaseOncology 1 Approved $6.66B 17
IMCR Immunocore DermatologyInfectious Disease+2 1 Approved $1.44B 12
INBX Inhibrx Biosciences Oncology 1 NDA Submitted $1.10B 6
KZIA Kazia Therapeutics NeurologyOncology Rare 1 Phase 2 $60.7M 13
KURA Kura Oncology MetabolicOncology 1 Approved $688M 13
LEGN Legend Biotech Oncology Rare 1 Approved $3.12B 17
MAIA MAIA Biotechnology Oncology 1 Phase 3 $77.2M 8
INKT MiNK Therapeutics ImmunologyOncology+1 Rare 2 Phase 2 $47.7M 8
NRIX Nurix Therapeutics ImmunologyNeurology+1 1 Phase 3 $1.56B 13
ONCY Oncolytics Biotech Oncology 1 Phase 2 $51.7M 4
PMVP PMV Pharmaceuticals Oncology 1 Phase 2 $92.2M 7
RVMD Revolution Medicines Oncology 2 Approved $35.2B 11
SMMT Summit Therapeutics Oncology 1 NDA Submitted $8.53B 6
SNDX Syndax Pharmaceuticals ImmunologyOncology Rare 1 Approved $822M 7
VSTM Verastem Oncology 1 Approved $934M 5
XNCR Xencor ImmunologyNeurology+1 Rare 1 Approved $2.59B 28